Pangea Biomed has partnered with the Sharett Institute of Oncology, Hadassah Cancer Research Institute, and Ultima Genomics to improve treatment predictions for solid tumor cancer using advanced genetic and transcriptomic profiling.
This collaboration includes comprehensive genetic profiling for patients with solid tumors at the Sharett Institute of Oncology. The data generated will be added to Pangea Biomed's AI-based ENLIGHT platform alongside RNA data from Ultima Genomics and whole-slide histopathology scans. The resulting reports, in conjunction with Hadassah's clinical analysis, are expected to enhance treatment choices for these patients. The long-term, multi-year project intends to generate a minimum of 2,000 ENLIGHT reports for patients annually.
Pangea Biomed is a precision oncology biotech company and the developer of ENLIGHT, an advanced multi-cancer, multi-therapy response predictor. ENLIGHT combines ML and deep RNA analysis to map tumor molecular signatures and personalize cancer care. It analyzes gene group behaviors and interactions to determine optimal treatment matches. The company's technology aims to increase the number of patients who can benefit from precision oncology treatments.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.